Angiotensin Converting Enzyme Inhibitors as Antihypertensive Therapy

  • A. Steiner
  • D. Edmonds
  • P. Greminger
  • W. Vetter
Part of the International Yearbooks of Nephrology book series (IYNE, volume 1)


Over the past ten years, angiotensin converting enzyme (ACE) inhibitors have become increasingly established in the therapy of hypertension and congestive heart failure. Worldwide experience to date with ACE inhibitors indicates that these agents are becoming one of the drugs of choice for large unselected hypertensive populations.


Essential Hypertension Angiotensin Converting Enzyme Inhibitor Plasma Renin Activity Renal Artery Stenosis Primary Aldosteronism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1).
    Frolich, E.D. Antihypertensive therapy: newer concepts and agents. Cardiol. 72: 349 – 365, 1985CrossRefGoogle Scholar
  2. 2).
    Ondetti M.A., Rubin B., Cushman D.W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Sience 196: 441, 1979CrossRefGoogle Scholar
  3. 3).
    Currie W.J.C., Cooper W.D. Safety of angiotensin-converting enzyme inhibitors. Lancet 1:580, 1985PubMedCrossRefGoogle Scholar
  4. 4).
    Atkinson A.B., Brown S.J., Cumming A.M.M., Fraser R., Lever A.F., Leckie B.J., Morton J.I., Robertson J.I.S., Davies D.L. Captopril in the management of hypertension with renal artery stenosis: its long term effect as a predictor of surgical outcome. Am. J. Cardiol. 49: 1460, 1982PubMedCrossRefGoogle Scholar
  5. 5).
    Salvetti A., Arzilli F., Nuccorini A., Simonini N., Glorioso N., Dessi-Fulgheri P., Madeddu P., Rappelli A. Acute response to Captopril as a predictive test for surgery in renovascular hypertension. Nephron 44: suppl.1 87, 1986PubMedCrossRefGoogle Scholar
  6. 6).
    Biollaz J., Waeber B., Brunner H.R. Hypertensive crisis treated by orally administered Captopril. Eur. J. Clin. Pharmacol. 25: 145, 1983PubMedCrossRefGoogle Scholar
  7. 7).
    Berel O., Marx B.E. Hypertensive emergencies. Nephron 47: suppl. 1,51, 1987CrossRefGoogle Scholar
  8. 8).
    Croog S.H., Levine S., Testa M.A., Brown B., Bulpitt C.J., Jenkins D., Klerma G.L., Williams G.H. The effects of antihypertensive therapy on the quality of life. N. Engl. J. Med. 314: 1657–1664, 1986PubMedCrossRefGoogle Scholar
  9. 9).
    Moncloa F., Sromovsky J.A., Walker J.F., Davies R.O. Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety. Drugs 30 (Suppl. 1) 82–89, 1985PubMedCrossRefGoogle Scholar
  10. 10).
    Yodfat Y., Fidel J., Bloom D.S. Captopril as a replacement for multiple therapy in hypertension: a controlled study. J. Hypertension 3 (Suppl. 2): 155–158, 1985Google Scholar
  11. 11).
    Morgan T.O., Sabto J., Anavekar S.N., Louis W.J., Doyle A.E. A comparison of beta adrenergic blocking drugs in the treatment of hypertension. Postgrad. Med. 50: 253–259, 1974CrossRefGoogle Scholar
  12. 12).
    Edmonds D., Knorr M., Greminger P., Walger P., Frielingsdorf J., Vetter H., Vetter W. ACE inhibitors versus beta-blocker in the treatment of essential hypertension. Nephron 47: 90, 1987PubMedCrossRefGoogle Scholar
  13. 13).
    Bergstrand R., Herlitz H., Johansson S., Berglund G., Vedin A., Wilhelmson C, Gomez HJ., Crillo V.J., Bolognese J.A. Effective dose range of enalapril in mild to moderate essential hypertension. Br. J. Clin. Pharmac. 19: 605–611, 1985Google Scholar
  14. 14).
    Brunner H.R., Waeber B. Nussberger J., Schaller M.D., Gomez H.J. Long-term clinical experience with enalapril in essential hypertension. J. Hypertension 1 (Suppl. 1): 103–107, 1983Google Scholar
  15. 15).
    Ayers C.R., Baker K.M., Weaver B.A., Lehman M.R. Enalapril maleate versus Captopril. A comparison of the hormonal and antihypertensive effect. Drugs 30 (Suppl. 1): 70–73, 1985PubMedCrossRefGoogle Scholar
  16. 16).
    Atkinson A.B., Lever A.F., Brown J.J., Robertson J.I.S. Combined treatment of severe intractable hypertension with Captopril and diuretic. Lancet 2: 105–108 1980PubMedCrossRefGoogle Scholar
  17. 17).
    Case D.B., Atlas S.A., Sullivan P.A., Laragh J.H. Acute and chronic treatment of severe and malignant hypertension with the oral angiotensin-converting enzyme inhibitor Captopril. Circulation 64: 765–771, 1981PubMedCrossRefGoogle Scholar
  18. 18).
    Atkinson A.B., Brown J.J., Cumming A.M.M., Fraser R., Lever A.F., Leckie B.J., Morton J.J., Robertson J.I.S., Davies D.L. Captopril in the management of hypertension with renal artery stenosis: its long term effect as a predictor of surgical outcome. Am. J. Cardiol. 49: 1460–1466, 1982PubMedCrossRefGoogle Scholar
  19. 19).
    Smith S.J., Markandu N.D., Mac Gregor G.A. Optimal dose of Captopril in hypertension. Lancet 2: 1460,1982PubMedCrossRefGoogle Scholar
  20. 20).
    Veterans Administration Cooperative Study Group on Antihypertensive Agents: Low-dose Captopril for the treatment of mild to moderate hypertension. Hypertension 5 (Supp. 3): 139–144, 1977Google Scholar
  21. 21).
    Greminger P., Foerster E., Vetter H., Baumgart P., Vetter W. Minoxidil and Captopril in severe hypertension. Klin. Wochenschr. 64: 327–332,1986PubMedCrossRefGoogle Scholar
  22. 22).
    Gavras H., Brunner H.R., Turini G.A., Kershaw G.R., Tift C.P., Cuttelod S., Gavras I., Vukovich R.A., McKinstry D.N. Antihypertensive effect of the oral angiotensin-converting enzyme inhibitor SQ 14.225 in man. N. Engl. J. Med. 298: 991–995, 1978PubMedCrossRefGoogle Scholar
  23. 23).
    Grüntzig A., Kuhlmann U., Vetter W., Lütolf U., Meier B., Siegenthaler W. Treatment of renovascular hypertension with percutaneous transluminal dilatation of a renal artery stenosis. Lancet 1: 801–802,1978PubMedCrossRefGoogle Scholar
  24. 24).
    Forster J.H., Maxwell M.H., Franklin S.S., Bleifer K.H., Trippeö O.H., Julian O.C., De Camp P.T., Varady P.T. Renovascular occlusive disease: results of operative treatment. J. Am. Med. Ass. 231: 1043–1048,1983CrossRefGoogle Scholar
  25. 25).
    Largiader F. Operative techniques in renovascular hypertension. Nephron 44 (Suppl. 1): 32–35, 1986PubMedGoogle Scholar
  26. 26).
    Grim C.E., Luft F.C., Yune H.Y., Klatte E.C., Weinberger M.H. Ann. Percutaneous transluminal dilatation in the treatment of renal vascular hypertension. Intern. Med. 95: 439–442, 1981Google Scholar
  27. 27).
    Hunt C.J., Strong C.G. Renovascular hypertension: mechanisms, natural history and treatment. Am. J. Cardiol. 32: 562–574,1973PubMedCrossRefGoogle Scholar
  28. 28).
    Case D.B., Atlas S.A., Laragh J.H. Long-term efficacy of Captopril in renovascular and essential hypertension. Am. J. Cardiol. 49: 1440–1446, 1982PubMedCrossRefGoogle Scholar
  29. 29).
    Coulie P., De Plaen J.F., van Yepersele de Strihou C. Captopril-induced acute reversible renal failure. Nephron 35, 108–111, 1983PubMedCrossRefGoogle Scholar
  30. 30).
    Hricik D.E., Broening P.J., Kopelman R., Goorno W.E., Madias N.E., Dzau V.J. N. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery Stenosis in a solitary kidney. Engl. J. Med. 308: 373–376, 1983CrossRefGoogle Scholar
  31. 31).
    Greminger P., Vetter H., Steurer J., Siegenthaler W., Vetter W. Captopril and kidney function in renovascular and essential hypertension. Nephron 44 (Suppl. 1): 91–95, 1986PubMedCrossRefGoogle Scholar
  32. 32).
    Watson M.L., Bell G.M., Muir A.L., Buist T.A.S., Kellet R.J., Padfield P.L. Captopril/diuretic combinations in severe renovascular disease. Lancet 2: 404–405, 1982Google Scholar
  33. 33).
    Brunner D.B., Desponds G., Biollaz J., Keller L, Ferber F., Gavras H., Brunner H.R., Schelling J.L. Effect of a new angiotensin-converting enzyme inhibitor MK-421 and its lysine analogue on the components of the renin system in healthy subjects. Br. J. Clin. Pharmac. 11: 461–467, 1981Google Scholar
  34. 34).
    Vaughan E.D. Jr., Carey R.M., Ayers CR., Peach M.J. Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme. J. Clin. Endocrinol. Metab. 48: 869–871, 1979PubMedCrossRefGoogle Scholar
  35. 35).
    Wauters J.P., Waeber B., Brunner H.R., Guignard J.P., Turini G.A:, Gavras H. Uncontrollable hypertension in patients on hemodialysis: long-term treatment with Captopril and salt subtraction. Clin. Nephrol. 16: 86–92, 1981PubMedGoogle Scholar
  36. 36).
    Davies D.L., Schalenkamp M.A., Beevers D.G., Brown J.J., Briggs J.D., Lever A.F., Medina A.M. Morton J.J., Robertson J.I.S., Tree M. Abnormal relation between exchangeable sodium and the renin-angiotensin system in malignant hypertension and in hypertension with chronic renal failure. Lancet 1: 683–686,1973PubMedCrossRefGoogle Scholar
  37. 37).
    Textor S.C., Bravo E.L., Fouad F.M., Tarazi R.C. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with Captopril. Am. J. Med. 73: 719–725, 1982PubMedCrossRefGoogle Scholar
  38. 38).
    Brunner H.R., Gavras H., Waeber B., Textor F.C., Turini G.A., Wauters J.P. Clinical use of an orally acting converting enzyme inhibitor: Captopril. Hypertension 2: 558–566, 1980PubMedGoogle Scholar
  39. 39).
    Mantero F., Fallo F., Opocher G., Armanini D., Boscaro M., Scaroni C. Effect of angiotensin II and converting enzyme inhibitor (Captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism. Clin. Sci. 61: 289s–293s, 1981PubMedGoogle Scholar
  40. 40).
    Stimpel W., Vetter W., Groth H., Greminger P., Vetter H. Captopril before and after spironolactone therapy in primary aldosteronism. Klin. Wochenschr. 63: 361–363, 1985PubMedCrossRefGoogle Scholar
  41. 41).
    Greminger P., Vetter W., Groth H., Lüscher T., Tenschert W., Siegenthaler W., Vetter H. Captopril in Cushing’s syndrome. Klin. Wochenschr. 62: 855–858, 1984PubMedCrossRefGoogle Scholar
  42. 42).
    Krakoff L., Nicolis G., Amsel B. Pathogenesis of hypertension in Cushing’s syndrome. Am.J.Med. 58: 216–220, 1975PubMedCrossRefGoogle Scholar
  43. 43).
    Broughton Pipkin F., Symonds E.M., Turner S.R. The effect of Captopril upon mother and fetus in the chronically cannulated ewe and in pregnant rabbit. J. Physiol. 323: 415–422, 1980Google Scholar
  44. 44).
    Ferris T.F., Weir E.K. Effect of Captopril on uterine blood flow and prostaglandin E synthesis in the pregnant rabbit. J.Clin. Invest: 71: 809–815, 1983PubMedCrossRefGoogle Scholar
  45. 45).
    Duminy P.C., Burger P.D. Fetal abnormality associated with the use of Captopril during pregnancy. S. Afr. Med. J. 60: 805, 1981PubMedGoogle Scholar
  46. 46).
    Creisson C, Baulac L., Lenfant B. Captopril/hydrochlorothiazide combination in elderly patients with mild — moderate hypertension. A double blind, randomized, placebo controlled study. Postgrad. Med. J. 62 (Suppl. 1): 139–141, 1986PubMedGoogle Scholar
  47. 47).
    Weidmann P., Gerber A., Mordasini R. Hypertension 5 (Suppl.3): 120–131, 1983Google Scholar
  48. 48).
    Bulpitt C.J. Serum uric acid in hypertensive patients. Br. Heart J. 37: 1210–1215, 1975PubMedCrossRefGoogle Scholar
  49. 49).
    Perez-Stable E., Caralis P.V. Thiazide-induced disturbances in carbohydrate, lipid, and potassium metabolism. Am. Heart J. 106, 245–251, 1983PubMedCrossRefGoogle Scholar
  50. 50).
    Groel J.T., Tadros S.S., Dreslinski G.R., Jenkins A.C. Long-term antihypertensive treatment with Captopril. Hypertension 5 (Suppl. 3): 145–151,1983Google Scholar
  51. 51).
    Malini P.L., Strocchi E., Ambrosini E., Magnani B. Long-term antihypertensive, metabolic and cellular effects of enalapril. J. Hypertension 2 (Suppl. 2): 101–105, 1984Google Scholar
  52. 52).
    Weinberger M,H. Influence of an angiotensin-converting enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension 5: suppl. 3, 132–138, 1983Google Scholar
  53. 53).
    Callender J.S., Hodsman G.P., Hutcheson M.J., Lever A. F., Robertson J.I.S. Mood changes during Captopril therapy for hypertension: a double-blind pilot study. Hypertension 5: suppl. 3, 90–93, 1983Google Scholar
  54. 54).
    Croog S.H., Levine S., Testa M.A., Brown B., Bulpitt C.J., Jenkins CD., Klerman G.L., Williams G.H. The effects of antihypertensive therapy on the quality of life. N. Engl. J. Med. 314: 1657 – 1664, 1986PubMedCrossRefGoogle Scholar
  55. 55).
    Edmonds D., Vetter H., Vetter W. Angiotensin-converting enzyme inhibitors in the clinic: quality of life. J. Hypertension 5 suppl.3: 31 – 35, 1987CrossRefGoogle Scholar
  56. 56).
    Mann A.H. Hypertension: psychological aspects and diagnostic impact in a clinical trial. Psychol. Med. suppl.5 Monog., 1977Google Scholar
  57. 57).
    Havelka J, Vetter H, Studer A, Greminger P, Luscher T, Wollnik S, Siegenthaler W, Vetter W. Acute and chronic effects of the angiotensin-converting enzyme inhibitor Captopril in severe hypertension. Am J Cardiol 49: 1467 – 1474,1982PubMedCrossRefGoogle Scholar
  58. 58).
    Ball SG, Robertson JIS. A need for new converting enzyme inhibitors? Br Med J 290: 180–181,1985CrossRefGoogle Scholar
  59. 59).
    Robertson JIS, Tillman DM. Treatment of hypertension with converting enzyme inhibitors. J Cardiovasc Pharmacol (in press)Google Scholar
  60. 60).
    C aptopril: benefits and risks in severe hypertension (editorial). Lancet 2: 129, 1980Google Scholar
  61. 61).
    Gavras I., Graff L.G., Rose B.D. et al. Fatal pancytopenia associated with the use of Captopril. Ann. Intern. Med. 94: 58, 1981PubMedGoogle Scholar
  62. 62).
    Marri A.E., Larabi M.S., Kechrid C. et al. Fatal bone-marrow suppression associated with Captopril. Br. Med. J. 283: 277, 1981Google Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • A. Steiner
    • 1
  • D. Edmonds
    • 1
  • P. Greminger
    • 1
  • W. Vetter
    • 1
  1. 1.Department of Internal MedicineUniversity HospitalZürichSwitzerland

Personalised recommendations